Latest Healthcare News

Emyria has expanded its Empax clinic network across four states, reporting a 210% revenue increase in FY26 and early clinical success in treatment-resistant depression.

Mach7 Technologies delivered a positive operating cash flow in Q4 FY26, boosted its ARR run rate by 7.6% in constant currency, and secured multi-year subscription deals while expanding its partner ecosystem.

Biome Australia capped FY26 with record $23.9 million sales and its flagship probiotic topping Australian pharmacy charts. The company signed an onshore manufacturing deal and expanded its proprietary probiotic clinical trial internationally.

Artrya is advancing its commercial footprint in the US with two health systems now generating revenue and FDA clearance for its Salix Coronary Flow module expected in H2 2026.

Cyclopharm’s Technegas® has been named the preferred ventilation agent in new US lung imaging guidelines, marking the first update in 14 years and potentially accelerating adoption across American hospitals.

Saluda Medical capped FY26 with a 28% revenue surge, beating guidance at US$90.2 million, while FDA approval for its CAP24 paddle lead opens a new US surgical market segment.

Vitrafy Life Sciences reported a breakthrough 94.4% post-thaw platelet recovery in US Army Phase II testing, secured major US blood network partnerships, and raised $32 million to accelerate US expansion and device manufacturing.

Adherium Limited has posted a fourth consecutive quarter of record remote patient monitoring revenue, driven by growing device activations and strong clinical evidence from the iCARE study, positioning the company for expanded value-based care contracts in the US.

InteliCare generated positive cash flow for the first time since listing in the June 2026 quarter, driven by accelerated deployments across aged care and retirement living sectors.

AMCIL posted a modest 3.6% net profit increase to $6.9 million for FY2026 despite a 10% portfolio loss. The company cut total dividends to 4.0 cents per share, reflecting market headwinds and portfolio repositioning.

dorsaVi has unveiled Sensor v6.5, its first wearable sensor that processes and acts on movement data in real time without cloud reliance, marking a key milestone in wearable Physical AI technology.

ImpediMed reported a 3% revenue increase to $3.6 million in Q4 FY26, bolstered by a $15.3 million capital raise and strategic leadership hires as it pushes growth in cancer survivorship, heart health, and weight management.